MX2022001013A - Degradador selectivo del receptor de estrogeno. - Google Patents
Degradador selectivo del receptor de estrogeno.Info
- Publication number
- MX2022001013A MX2022001013A MX2022001013A MX2022001013A MX2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- selective estrogen
- receptor degrader
- chromen
- enyl
- Prior art date
Links
- 229940125944 selective estrogen receptor degrader Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- DVZLOPUYTKPWHJ-NSCUHMNNSA-N 3-(3,5-difluorophenyl)-2-[4-[(E)-3-[3-(fluoromethyl)azetidin-1-yl]prop-1-enyl]phenyl]-4-methyl-2H-chromen-7-ol Chemical compound FC=1C=C(C=C(C=1)F)C=1C(OC2=CC(=CC=C2C=1C)O)C1=CC=C(C=C1)\C=C\CN1CC(C1)CF DVZLOPUYTKPWHJ-NSCUHMNNSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029554 | 2019-07-22 | ||
| PCT/IB2020/056914 WO2021014386A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001013A true MX2022001013A (es) | 2022-02-22 |
Family
ID=71842730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001013A MX2022001013A (es) | 2019-07-22 | 2020-07-22 | Degradador selectivo del receptor de estrogeno. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11014915B2 (https=) |
| EP (1) | EP4003525A1 (https=) |
| JP (1) | JP2022541938A (https=) |
| KR (1) | KR20220046586A (https=) |
| CN (1) | CN114302879A (https=) |
| AU (1) | AU2020317099A1 (https=) |
| BR (1) | BR112022001285A2 (https=) |
| CA (1) | CA3148592A1 (https=) |
| CL (1) | CL2022000156A1 (https=) |
| IL (1) | IL290036A (https=) |
| MX (1) | MX2022001013A (https=) |
| PE (1) | PE20221588A1 (https=) |
| PH (1) | PH12022550182A1 (https=) |
| WO (1) | WO2021014386A1 (https=) |
| ZA (1) | ZA202201157B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) * | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| CN114127054B (zh) | 2019-07-22 | 2024-04-09 | 勃林格殷格翰国际有限公司 | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 |
| KR20220046586A (ko) * | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
| CA3243621A1 (en) * | 2022-02-01 | 2023-08-10 | Eli Lilly And Company | METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| EP0470310B1 (en) | 1990-08-09 | 1995-11-29 | Council of Scientific and Industrial Research | Novel benzopyrans and process for their production |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| CA2915534A1 (en) * | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| CN103879283B (zh) * | 2014-03-10 | 2019-01-15 | 浙江吉利汽车研究院有限公司 | 一种电动车辆 |
| US20160175284A1 (en) * | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
| WO2017072792A1 (en) * | 2015-10-27 | 2017-05-04 | Sun Pharma Advanced Research Company Limited | Novel heterocyclic antiestrogens |
| KR20220046586A (ko) * | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
-
2020
- 2020-07-22 KR KR1020227005904A patent/KR20220046586A/ko not_active Ceased
- 2020-07-22 AU AU2020317099A patent/AU2020317099A1/en not_active Abandoned
- 2020-07-22 JP JP2022504655A patent/JP2022541938A/ja active Pending
- 2020-07-22 CN CN202080053315.6A patent/CN114302879A/zh active Pending
- 2020-07-22 US US16/936,022 patent/US11014915B2/en active Active
- 2020-07-22 WO PCT/IB2020/056914 patent/WO2021014386A1/en not_active Ceased
- 2020-07-22 EP EP20747136.8A patent/EP4003525A1/en not_active Withdrawn
- 2020-07-22 CA CA3148592A patent/CA3148592A1/en active Pending
- 2020-07-22 PE PE2022000135A patent/PE20221588A1/es unknown
- 2020-07-22 BR BR112022001285A patent/BR112022001285A2/pt not_active IP Right Cessation
- 2020-07-22 PH PH1/2022/550182A patent/PH12022550182A1/en unknown
- 2020-07-22 MX MX2022001013A patent/MX2022001013A/es unknown
-
2021
- 2021-05-05 US US17/308,501 patent/US20210261534A1/en not_active Abandoned
-
2022
- 2022-01-22 CL CL2022000156A patent/CL2022000156A1/es unknown
- 2022-01-23 IL IL290036A patent/IL290036A/en unknown
- 2022-01-25 ZA ZA2022/01157A patent/ZA202201157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201157B (en) | 2023-07-26 |
| CL2022000156A1 (es) | 2022-11-18 |
| WO2021014386A1 (en) | 2021-01-28 |
| PE20221588A1 (es) | 2022-10-10 |
| JP2022541938A (ja) | 2022-09-28 |
| PH12022550182A1 (en) | 2022-11-14 |
| EP4003525A1 (en) | 2022-06-01 |
| BR112022001285A2 (pt) | 2022-03-22 |
| KR20220046586A (ko) | 2022-04-14 |
| CA3148592A1 (en) | 2021-01-28 |
| US20210024504A1 (en) | 2021-01-28 |
| US11014915B2 (en) | 2021-05-25 |
| AU2020317099A1 (en) | 2022-02-24 |
| CN114302879A (zh) | 2022-04-08 |
| IL290036A (en) | 2022-03-01 |
| US20210261534A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001013A (es) | Degradador selectivo del receptor de estrogeno. | |
| MX2021009569A (es) | Procesos y compuestos. | |
| PH12021550296A1 (en) | Substituted indoles and methods of use thereof | |
| MX2023010043A (es) | Moduladores del receptor de androgenos y metodos para su uso. | |
| EP3773552A4 (en) | COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | |
| CY1121071T1 (el) | Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων | |
| UY30292A1 (es) | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico | |
| UA122528C2 (uk) | Сполуки, які модулюють fxr (nr1h4) | |
| EA201792394A3 (ru) | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака | |
| MX392461B (es) | Moduladores de receptores estrogénicos | |
| MA56553B1 (fr) | Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk | |
| CL2008001213A1 (es) | Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer. | |
| UY32352A (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| UY33118A (es) | Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos | |
| EP4212532A3 (en) | Mitragynine analogs and uses thereof | |
| MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| PE20160050A1 (es) | Inhibidores/ antiandrogenos novedosos de cyp17 | |
| CO2023001848A2 (es) | Compuestos de indol como moduladores de los receptores de andrógenos | |
| PH12014501157A1 (en) | Pharmaceutical formulations | |
| BR112014016635B8 (pt) | composto, composição, e, uso de um composto | |
| MX378389B (es) | Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| UY33722A (es) | Oxazolidinonas como moduladores de mglur5 |